Selected research
Industry Growth & Trends
Global Blood Plasma Derivatives Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Blood Plasma Derivatives market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Blood Plasma Derivatives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Blood Plasma Derivatives market include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Blood Plasma Derivatives market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Blood Plasma Derivatives market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Blood Plasma Derivatives market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Blood Plasma Derivatives.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Blood Plasma Derivatives market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Blood Plasma Derivatives Market by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Blood Plasma Derivatives Segment by Type
Albumin
Coagulation Factor
Immune Globulin
Other
Blood Plasma Derivatives Segment by Application
Hospital
Retail Pharmacy
Other
Blood Plasma Derivatives Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma Derivatives.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Blood Plasma Derivatives companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Coagulation Factor
- Immune Globulin
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- CBPO
- Shuanglin Bio
- RAAS
- Nanyue Bio
- Hualan Bio
- Boya Bio
- Octapharma
- LFB Group
- KM Biologics
- Kedrion
- Grifols
- CSL
- BPL
- Biotest
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Blood Plasma Derivatives Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Blood Plasma Derivatives Market Size by Region (2021-2032)
- 1.4.1 Global Blood Plasma Derivatives Market Size by Region (2021-2026)
- 1.4.2 Global Blood Plasma Derivatives Market Size by Region (2027-2032)
- 1.5 Key Regions Blood Plasma Derivatives Market Size (2021-2032)
- 1.5.1 North America Blood Plasma Derivatives Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Blood Plasma Derivatives Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Blood Plasma Derivatives Market Size Growth Rate (2021-2032)
- 1.5.4 South America Blood Plasma Derivatives Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Blood Plasma Derivatives Market Size Growth Rate (2021-2032)
2 Blood Plasma Derivatives Market by Type
- 2.1 Type Introduction
- 2.1.1 Albumin
- 2.1.2 Coagulation Factor
- 2.1.3 Immune Globulin
- 2.1.4 Other
- 2.2 Global Blood Plasma Derivatives Market Size by Type
- 2.2.1 Global Blood Plasma Derivatives Market Size Overview by Type (2021-2032)
- 2.2.2 Global Blood Plasma Derivatives Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Blood Plasma Derivatives Market Size Forecasted by Type (2027-2032)
- 2.3 Global Blood Plasma Derivatives Market Size by Regions
- 2.3.1 North America Blood Plasma Derivatives Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Blood Plasma Derivatives Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Blood Plasma Derivatives Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Blood Plasma Derivatives Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Blood Plasma Derivatives Market Size Breakdown by Type (2021-2026)
3 Blood Plasma Derivatives Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Retail Pharmacy
- 3.1.3 Other
- 3.2 Global Blood Plasma Derivatives Market Size by Application
- 3.2.1 Global Blood Plasma Derivatives Market Size Overview by Application (2021-2032)
- 3.2.2 Global Blood Plasma Derivatives Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Blood Plasma Derivatives Market Size Forecasted by Application (2027-2032)
- 3.3 Global Blood Plasma Derivatives Market Size by Regions
- 3.3.1 North America Blood Plasma Derivatives Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Blood Plasma Derivatives Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Blood Plasma Derivatives Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Blood Plasma Derivatives Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Blood Plasma Derivatives Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Blood Plasma Derivatives Industry Trends
- 4.2 Blood Plasma Derivatives Industry Drivers
- 4.3 Blood Plasma Derivatives Industry Opportunities and Challenges
- 4.4 Blood Plasma Derivatives Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Blood Plasma Derivatives Revenue (2021-2026)
- 5.2 Global Blood Plasma Derivatives Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Blood Plasma Derivatives Key Company Headquarters & Area Served
- 5.4 Global Blood Plasma Derivatives Company, Product Type & Application
- 5.5 Global Blood Plasma Derivatives Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Blood Plasma Derivatives Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Blood Plasma Derivatives Players Market Share by Revenue in 2025
- 5.6.3 2025 Blood Plasma Derivatives Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Yuanda Shuyang
- 6.1.1 Yuanda Shuyang Company Information
- 6.1.2 Yuanda Shuyang Business Overview
- 6.1.3 Yuanda Shuyang Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Yuanda Shuyang Blood Plasma Derivatives Product Portfolio
- 6.1.5 Yuanda Shuyang Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Takeda Blood Plasma Derivatives Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 Weiguang Bio
- 6.3.1 Weiguang Bio Company Information
- 6.3.2 Weiguang Bio Business Overview
- 6.3.3 Weiguang Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Weiguang Bio Blood Plasma Derivatives Product Portfolio
- 6.3.5 Weiguang Bio Recent Developments
- 6.4 Tiantan Bio
- 6.4.1 Tiantan Bio Company Information
- 6.4.2 Tiantan Bio Business Overview
- 6.4.3 Tiantan Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Tiantan Bio Blood Plasma Derivatives Product Portfolio
- 6.4.5 Tiantan Bio Recent Developments
- 6.5 CBPO
- 6.5.1 CBPO Company Information
- 6.5.2 CBPO Business Overview
- 6.5.3 CBPO Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 CBPO Blood Plasma Derivatives Product Portfolio
- 6.5.5 CBPO Recent Developments
- 6.6 Shuanglin Bio
- 6.6.1 Shuanglin Bio Company Information
- 6.6.2 Shuanglin Bio Business Overview
- 6.6.3 Shuanglin Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Shuanglin Bio Blood Plasma Derivatives Product Portfolio
- 6.6.5 Shuanglin Bio Recent Developments
- 6.7 RAAS
- 6.7.1 RAAS Company Information
- 6.7.2 RAAS Business Overview
- 6.7.3 RAAS Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 RAAS Blood Plasma Derivatives Product Portfolio
- 6.7.5 RAAS Recent Developments
- 6.8 Nanyue Bio
- 6.8.1 Nanyue Bio Company Information
- 6.8.2 Nanyue Bio Business Overview
- 6.8.3 Nanyue Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Nanyue Bio Blood Plasma Derivatives Product Portfolio
- 6.8.5 Nanyue Bio Recent Developments
- 6.9 Hualan Bio
- 6.9.1 Hualan Bio Company Information
- 6.9.2 Hualan Bio Business Overview
- 6.9.3 Hualan Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Hualan Bio Blood Plasma Derivatives Product Portfolio
- 6.9.5 Hualan Bio Recent Developments
- 6.10 Boya Bio
- 6.10.1 Boya Bio Company Information
- 6.10.2 Boya Bio Business Overview
- 6.10.3 Boya Bio Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Boya Bio Blood Plasma Derivatives Product Portfolio
- 6.10.5 Boya Bio Recent Developments
- 6.11 Octapharma
- 6.11.1 Octapharma Company Information
- 6.11.2 Octapharma Business Overview
- 6.11.3 Octapharma Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Octapharma Blood Plasma Derivatives Product Portfolio
- 6.11.5 Octapharma Recent Developments
- 6.12 LFB Group
- 6.12.1 LFB Group Company Information
- 6.12.2 LFB Group Business Overview
- 6.12.3 LFB Group Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 LFB Group Blood Plasma Derivatives Product Portfolio
- 6.12.5 LFB Group Recent Developments
- 6.13 KM Biologics
- 6.13.1 KM Biologics Company Information
- 6.13.2 KM Biologics Business Overview
- 6.13.3 KM Biologics Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 KM Biologics Blood Plasma Derivatives Product Portfolio
- 6.13.5 KM Biologics Recent Developments
- 6.14 Kedrion
- 6.14.1 Kedrion Company Information
- 6.14.2 Kedrion Business Overview
- 6.14.3 Kedrion Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Kedrion Blood Plasma Derivatives Product Portfolio
- 6.14.5 Kedrion Recent Developments
- 6.15 Grifols
- 6.15.1 Grifols Company Information
- 6.15.2 Grifols Business Overview
- 6.15.3 Grifols Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Grifols Blood Plasma Derivatives Product Portfolio
- 6.15.5 Grifols Recent Developments
- 6.16 CSL
- 6.16.1 CSL Company Information
- 6.16.2 CSL Business Overview
- 6.16.3 CSL Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 CSL Blood Plasma Derivatives Product Portfolio
- 6.16.5 CSL Recent Developments
- 6.17 BPL
- 6.17.1 BPL Company Information
- 6.17.2 BPL Business Overview
- 6.17.3 BPL Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 BPL Blood Plasma Derivatives Product Portfolio
- 6.17.5 BPL Recent Developments
- 6.18 Biotest
- 6.18.1 Biotest Company Information
- 6.18.2 Biotest Business Overview
- 6.18.3 Biotest Blood Plasma Derivatives Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Biotest Blood Plasma Derivatives Product Portfolio
- 6.18.5 Biotest Recent Developments
7 North America
- 7.1 North America Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Blood Plasma Derivatives Market Size by Country (2021-2026)
- 7.3 North America Blood Plasma Derivatives Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Blood Plasma Derivatives Market Size by Country (2021-2026)
- 8.3 Europe Blood Plasma Derivatives Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Blood Plasma Derivatives Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Blood Plasma Derivatives Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Blood Plasma Derivatives Market Size by Country (2021-2026)
- 10.3 South America Blood Plasma Derivatives Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Blood Plasma Derivatives Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Blood Plasma Derivatives Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst